Laboratory Evaluation for Systemic Lupus Erythematosus

Initial Diagnostic Testing

The American College of Rheumatology recommends beginning with ANA testing using a 1:160 dilution cutoff as the initial screening test, followed by a comprehensive autoantibody panel and baseline laboratory workup when ANA is positive 1
ANA serves as the entry criterion, with 1:160 dilution cutoff to minimize false positives in unselected populations 1
Anti-dsDNA antibodies should be measured using a double-screening strategy, and correlates with disease activity and active renal disease, making it essential for both diagnosis and monitoring 1, 2, 3

Anti-Sm antibodies provide prognostic value and are part of the essential baseline panel 2
Anti-Ro and anti-La antibodies must be checked at baseline due to their association with neonatal lupus risk, making them critical before pregnancy 2, 3
Anti-RNP antibodies offer prognostic information 2, 3
Anti-phospholipid antibodies are essential at baseline given their association with thrombotic events, damage development, and pregnancy complications 2, 3

Measure C3 and C4 at baseline, as low complement predicts flares and correlates with active disease, especially renal involvement 1, 2
Low complement combined with positive anti-dsDNA strongly supports active SLE 1

Complete blood count is mandatory at baseline to detect cytopenias, and severe anemia associates with organ involvement, disease progression, and worse prognosis 2, 3
Thrombocytopenia correlates with renal disease, progression to end-stage renal disease, and higher mortality 3
Severe leukopenia and lymphopenia increase infection risk significantly 2, 3

ESR should be measured at baseline and for ongoing monitoring 2
CRP has important clinical utility, and significantly elevated CRP suggests superimposed infection with 80-84% specificity 2, 4

Serum creatinine provides prognostic information about renal involvement 2
Serum albumin indicates renal involvement and poor prognosis when low 2, 3
Urinalysis with urine protein/creatinine ratio is essential for detecting and monitoring nephritis 2

Total IgG and IgG subclass levels should be assessed at first evaluation, particularly in patients who will receive immunosuppressive drugs 3
Low IgG3 or IgG4 associate with increased infection risk 3

Monitor every 6-12 months in patients with inactive disease, absent organ damage, and no comorbidities 2, 3
More frequent monitoring is required when reducing immunosuppressive therapy, especially in renal disease which may recur without symptoms 2, 3
Repeat anti-dsDNA and complement levels at follow-up visits even if previously negative/normal 2
CBC, ESR, CRP, serum albumin, creatinine, and urinalysis should be repeated at each monitoring visit 2

CMV antigenaemia testing should be considered in patients with active disease receiving high-dose glucocorticoids, as CMV infection may mimic active SLE 3, 4
Anti-C1q antibodies have nearly 100% prevalence during active lupus nephritis with critical negative predictive value 1
Persistent anti-dsDNA antibodies and hypocomplementemia after treatment indicate high risk for renal relapse 1